Evidence map›Paper›PMID 36078942›Full record

ArticleJournal of clinical medicine2022

Evaluation of Glycosylated Ferritin in Adult-Onset Still's Disease and Differential Diagnoses.

Arthur Guerber, Etienne Garneret, Thomas El Jammal, Sabine Zaepfel, Mathieu Gerfaud-Valentin, Pascal Sève, Yvan Jamilloux

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Arthur GuerberInternal Medicine, University Hospital Croix-Rousse, Hospices Civils de Lyon, 69004 Lyon, France.
Etienne GarneretInternal Medicine, University Hospital Croix-Rousse, Hospices Civils de Lyon, 69004 Lyon, France.
Thomas El JammalInternal Medicine, University Hospital Croix-Rousse, Hospices Civils de Lyon, 69004 Lyon, France.
Sabine ZaepfelBiochemistry Department, University Hospital Croix-Rousse, Hospices Civils de Lyon, 69004 Lyon, France.
Mathieu Gerfaud-ValentinInternal Medicine, University Hospital Croix-Rousse, Hospices Civils de Lyon, 69004 Lyon, France.ORCID 0000-0003-4245-8039
Pascal SèveInternal Medicine, University Hospital Croix-Rousse, Hospices Civils de Lyon, 69004 Lyon, France.ORCID 0000-0003-3070-3842
Yvan JamillouxInternal Medicine, University Hospital Croix-Rousse, Hospices Civils de Lyon, 69004 Lyon, France.ORCID 0000-0001-5249-3650
Université Claude Bernard Lyon 1 · FRHospices Civils de Lyon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycosylated ferritin (GF) has been reported as a good diagnostic biomarker for adult-onset Still’s disease (AOSD), but only a few studies have validated its performance. We performed a retrospective study of all adult patients with at least one GF measurement over a 2-year period in one hospital laboratory. The diagnosis of AOSD was based on the expert opinion of the treating physician and validated by two independent investigators. Patients’ characteristics, disease activity, and outcome were recorded and compared. Twenty-eight AOSD and 203 controls were identified. Compared to controls, the mean GF was significantly lower (22.3% vs. 39.3, p < 0.001) in AOSD patients. GF had a high diagnostic accuracy for AOSD, independent of disease activity or total serum ferritin (AUC: 0.674 to 0.915). The GF optimal cut-off value for AOSD diagnosis was 16%, yielding a specificity of 89% and a sensitivity of 63%. We propose a modified diagnostic score for AOSD, based on Fautrel’s criteria but with a GF threshold of 16% that provides greater specificity and increases the positive predictive value by nearly 5 points. GF is useful for ruling out differential diagnoses and as an appropriate classification criterion for use in AOSD clinical trials.

Indexed as

adult-onset Still’s diseasediagnostic accuracyglycosylated ferritinhemophagocytic lympho-histiocytosis

Identifiers

PMID36078942
PMCPMC9456550
OpenAlexW4293427649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.